CN Patent

CN111868039A — 用于治疗癌症的组合物和方法

Assigned to University of California San Diego UCSD · Expires 2020-10-30 · 6y expired

What this patent protects

本公开涉及能够渗透到血脑屏障中以调节EGFR酪氨酸激酶的活性的化合物。本公开还涉及治疗胶质母细胞瘤和其他EGFR介导的癌症的方法。本公开还涉及治疗胶质母细胞瘤和已被确定在抑制剂存在时具有改变的葡萄糖代谢的其他EGFR介导的癌症的方法。本公开还提供向受试者施用葡萄糖代谢抑制剂和细胞质p53稳定剂的方法。

USPTO Abstract

本公开涉及能够渗透到血脑屏障中以调节EGFR酪氨酸激酶的活性的化合物。本公开还涉及治疗胶质母细胞瘤和其他EGFR介导的癌症的方法。本公开还涉及治疗胶质母细胞瘤和已被确定在抑制剂存在时具有改变的葡萄糖代谢的其他EGFR介导的癌症的方法。本公开还提供向受试者施用葡萄糖代谢抑制剂和细胞质p53稳定剂的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111868039A
Jurisdiction
CN
Classification
—
Expires
2020-10-30
Drug substance claim
No
Drug product claim
No
Assignee
University of California San Diego UCSD
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.